After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Coherus, meanwhile, says Yusimry is being offered at an 85% discount to the brand, at $995 for a box of two autoinjectors, which is equivalent to around $13,000 per year versus $85,000 for Humira.

A West Virginia University legal scholar says current laws may be giving manufacturers of biologic drugs, like antibodies and ...

Here’s how it works. I’ve tested a lot of mattresses in a box, so I know they're just as comfortable as traditional mattresses. The biggest difference is packaging and delivery: boxed ...

Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...

The fully human anti-TNF-α antibody adalimumab (Humira; Abbott ... and the drug label contains a black-box warning of the risk of serious infections 6. Certolizumab pegol is approved by the ...

Dr Joseph F Kerbleski, Department of Dermatology, Tufts Medical Center, 800 Washington St, Box 114, Boston, MA 02111, USA ... Philadelphia, USA), adalimumab (Humira; Abbott Laboratories, Abbott Park, ...

In October, the insurer negotiated with a subsidiary of German manufacturer Fresenius for a biosimilar of Humira, AbbVie’s blockbuster drug that treats a variety of inflammatory conditions.

Teva Pharmaceutical Industries Limited ( NYSE: TEVA) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Richard Francis - President and CEO Eric Hughes - Head of R&D and Chief ...

Crohn's disease and ulcerative colitis are idiopathic, chronic, relapsing, inflammatory conditions that are immunologically mediated. Although their exact etiologies remain uncertain, results from ...

In October, the insurer negotiated with a subsidiary of German manufacturer Fresenius for a biosimilar of Humira, AbbVie’s blockbuster drug that treats a variety of inflammatory conditions. A ...